Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak occurred on August 19,

MRK remains a defensive, yield-generating diversification play, but near-term upside appears constrained by valuation and expectations.

Merck (MRK) stock surged 12.12% after positive Phase 3 melanoma trial results with Moderna showed improved survival rates for intismeran plus KEYTRUDA.

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology.

In a regulatory filing on August 10, pharmaceutical titan Merck & Company, Inc. (NYSE:MRK) disclosed holding 1,214,126 shares of micro-cap AI immunology firm Evaxion A/S (NASDAQ:EVAX). Evaxion shares bumped up 2% to $3.

<?xml encoding="utf-8" ?> Editor’s note: This story and headline have been corrected to reflect that BNT122 is a BioNTech and Genentech program. Merck & Co., Inc. MRK and Moderna, Inc. MRNA have delivered the first Phase 3 win for a personalized cancer vaccine,

Oncology R&D organization Sarah Cannon Research Institute (SCRI) announced a collaboration with Merck & Co. to bolster patient access to community-based oncology trials. | Oncology R&D organization Sarah Cannon Research Institute (SCRI) announced a collaboration with Merck & Co.

New Drugs Are Driving Revenue Merck & Co. recently released its second-quarter results. The US company remains strategically on track. The focus is on diversifying the product portfolio ahead of the expiration of Keytruda’s main patents in 2028.